Lilly's ADHD drug Strattera receives new warning labels from FDA

07/16/2012 |

The FDA issued new safety warning labels for Eli Lilly and Co.'s attention-deficit/hyperactivity disorder treatment Strattera, or atomoxetine, for people with serious heart conditions. The agency reviewed clinical trials and found that 5% to 10% of adults and children experienced increases in blood pressure and heart rate while on the drug.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA